Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study

Oramed Pharmaceuticals Inc. announced that it has enrolled and randomized over 75% of the 675 patients planned for its Phase III ORA-D-013-1 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes.